BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li L, Chen NN, You QD, Xu XL. An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opin Ther Pat 2021;31:67-80. [PMID: 32990109 DOI: 10.1080/13543776.2021.1829595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Serapian SA, Sanchez-Martín C, Moroni E, Rasola A, Colombo G. Targeting the mitochondrial chaperone TRAP1: strategies and therapeutic perspectives. Trends Pharmacol Sci 2021;42:566-76. [PMID: 33992469 DOI: 10.1016/j.tips.2021.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Dent P, Booth L, Roberts JL, Poklepovic A, Cridebring D, Reiman EM. Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43. Aging (Albany NY) 2021;13:17097-117. [PMID: 34252884 DOI: 10.18632/aging.203297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vannas C, Andersson L, Dolatabadi S, Ranji P, Lindén M, Jonasson E, Ståhlberg A, Fagman H, Åman P. Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines 2022;10:624. [DOI: 10.3390/biomedicines10030624] [Reference Citation Analysis]
4 Roberts RJ, Hallee L, Lam CK. The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases. J Pers Med 2021;11:1373. [PMID: 34945845 DOI: 10.3390/jpm11121373] [Reference Citation Analysis]
5 Gu C, Wang Y, Zhang L, Qiao L, Sun S, Shao M, Tang X, Ding P, Tang C, Cao Y, Zhou Y, Guo M, Wei R, Li N, Xiao Y, Duan J, Yang Y. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res 2022;41:11. [PMID: 34991674 DOI: 10.1186/s13046-021-02220-1] [Reference Citation Analysis]